MARKET

NUVB-WS

NUVB-WS

Nuvation Bio Inc
NYSE

Real-time Quotes | Nasdaq Last Sale

2.400
0.000
0.00%
Closed 16:00 09/24 EDT
OPEN
--
PREV CLOSE
2.400
HIGH
--
LOW
--
VOLUME
0
TURNOVER
--
52 WEEK HIGH
5.12
52 WEEK LOW
1.540
MARKET CAP
--
P/E (TTM)
-6.4760
1D
5D
1M
3M
1Y
5Y
BRIEF-Nuvation Bio Reports Second Quarter 2021 Financial Results And Provides Business Update
reuters.com · 08/12 22:12
BRIEF-Nuvation Bio Expects To Submit Up To Five Additional Investigational NDA With U.S. FDA By 2026
reuters.com · 03/11 23:08
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of NUVB-WS. Analyze the recent business situations of Nuvation Bio Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
EPS
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.13%
Pharmaceuticals & Medical Research
-1.02%
Key Executives
Non-Executive Chairman/Independent Director
Daniel Welch
President/Chief Executive Officer/Founder/Director
David Hung
Chief Financial Officer
Jennifer Fox
Senior Vice President/Director of Human Resources
Stacy Markel
Senior Vice President
Thomas Templeman
Chief Scientific Officer
Gary Hattersley
Executive Officer
Sergey Yurasov
Director
Oleg Nodelman
Independent Director
Robert Bazemore
Independent Director
Kim Blickenstaff
Independent Director
Michelle Doig
Independent Director
Kathryn Falberg
Independent Director
W. Anthony Vernon
No Data
About NUVB-WS
Nuvation Bio, Inc, formerly Panacea Acquisition Corp, is a biopharmaceutical company. The Company is engaged in developing differentiated and novel therapeutic candidates. Its portfolio includes distinct oncology therapeutic product candidates, each targeting some of the difficult-to-treat types of cancer. The Company’s drug discovery and development programs include a cyclin-dependent kinase (CDK) inhibitor program, a bromodomain and extra terminal protein (BET) inhibitor program, a WEE1 inhibitor program, an A2A adenosine receptor inhibitor program, and a drug-drug conjugate (DDC) platform that has compounds targeting hormone-driven cancers such as prostate, breast and ovarian cancers.

Webull offers kinds of Nuvation Bio Inc stock information, including NYSE:NUVB WS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NUVB WS stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading NUVB-WS stock methods without spending real money on the virtual paper trading platform.